Oviva Diabetes Remission
For the first time we are opening our Diabetes Remission programme to people with Type 2 diabetes who are on insulin therapy.
This digital programme is the first of its kind in the world, and widening access to 62,000 people a year will save more than £2.29 million a year in Type 2 Diabetes management costs across medications, monitoring, and hospital and GP usage.
If you’d like join us and transform the lives of patients in your area get in touch.
- Clinically effective
- Clinically safe
- Cost effective
The NHS spent £1.2 billion on diabetes prescribing in 2020, of which £353 million was on insulin.1
People on insulin have the highest risk of serious complications from their diabetes or from their treatment itself but to date they have not been able to access low calorie diet or remission services due to concerns around safety and a lack of good quality evidence.
Evidence has shown that intensive dietary intervention can
help people with Type 2 diabetes achieve remission through
rapid weight loss (15kg).2
Why should you commission Oviva Diabetes Remission?
Oviva has extensive experience in delivering diabetes remission services since 2014. We’ve also been a provider of the NHS Type 2 Diabetes Path to Remission programme since it launched in 2020.
Our multidisciplinary team ensures participant safety throughout the programme
- Our multidisciplinary team enables us to make medication adjustments from the point of referral and throughout the 12 months
- We utilise an insulin withdrawal algorithm, during the insulin adjustment stages. This provides intensive glucose monitoring, beyond any previous trial design
- The programme has eligibility and exclusion criteria that seek to minimise risk from the outset
For more information about our clinical safety for Diabetes Remission, please contact us.
We have the potential to save the NHS more than £229 million a year
- The average patient with Type 2 diabetes receiving insulin and other medications costs the NHS £850 per annum in prescribing costs3
- Oviva Diabetes Remission can reduce these costs through deprescribing and potential remission
- Enabling 62,000 people with Type 2 diabetes on insulin therapy to access this programme will save more than £229 million a year in Type 2 Diabetes management costs across medications, monitoring, and hospital and GP usage
For more information about our cost effective programmes, please contact us.
We support people achieve significant clinical outcomes while reducing medication need
|12 week Total Diet Replacement completion rate||93%|
|Average body weight reduction at 12 months4||-14.7kg|
|Average HbA1c reduction||33%|
|Prescriptions stopped on average per participant||3.3|
|Average Type 2 diabetes remission rate||63%|
For more information about our clinical outcomes, please contact us.
Commissioning Oviva Diabetes Remission
At Oviva we pride ourselves on providing person-centric care that is not only accessible, but safe and effective. That’s why we have evolved our successful Diabetes Remission programme to support people with Type 2 diabetes who may be excluded from the NHS Type 2 Diabetes Path to Remission programme.
Differences between the National programme and Oviva Diabetes Remission
|NHS Type 2 Diabetes Path to Remission||Oviva Diabetes Remission|
|Referral||Primary care||Primary care|
|Eligibility||Adults aged <65||Adults aged >65|
|Not on insulin||On insulin therapy|
|Diagnosis <6 years||Diagnosis >6 years|
|Objectives||Weight loss||Weight loss|
|Medication reduction, including insulin|
“People on insulin have the highest risk of serious complications from their diabetes or from their treatment itself. They are not able to access low calorie diet or remission services due to concerns around safety and a lack of good quality evidence.
Through our research, we will develop and evaluate a safe, effective, and remote low calorie diet programme for people on insulin therapy, a first of its kind in the world.”
Dr Neel Gupta, UK Medical Lead
Keep in touch!
If you’d like to stay up-to-date with our latest diabetes remission news, data and trials, sign up to join our mailing list.